Associations between metabolic disorders and risk of cancer in Danish men and women - a nationwide cohort study

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Berger, Siv Mari ^a   Gislason, Gunnar ^a,d,e   Moore, Lynn L ^c   Andersson, Charlotte ^a   Torp Pedersen, Christian ^b   Denis, Gerald V ^c   Schmiegelow, Michelle Dalgas ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e The Danish Heart Foundation   (Denmark)

Author keywords

Cancer; Diabetes; Epidemiology; Hypercholesterolemia; Hypertension; Metabolic

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RISK; COHORT ANALYSIS; DANISH CITIZEN; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MIDDLE AGED; RISK ASSESSMENT; SEX DIFFERENCE; SEX RATIO; VERY ELDERLY; WOMEN'S HEALTH; YOUNG ADULT; DENMARK; NEOPLASMS; REGISTER; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DENMARK; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK FACTORS; YOUNG ADULT;

EID: 84958970690     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2122-7     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2929.
3. Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, et al. A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol. 2013;107(2):221-6.
4. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-36.
5. Mortality and burden of disease attributable to selected major risks [ http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf ] 20 April 2015.
6. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-78.
7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-91.
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
9. Emerging Risk Factors C, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-95.
10. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34(1):210-5.
11. Moore LL, Chadid S, Singer MR, Kreger BE, Denis GV. Metabolic health reduces risk of obesityrelated cancer in Framingham Study adults. The Framingham Study. Cancer Epidemiology, Biomarkers and Prevention. 2014;23:2057-65.
12. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009;6(12):e1000201.
13. Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59(4):802-10.
14. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-11.
15. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-8.
16. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National registry of patients. BMC Med Res Methodol. 2011;11:83.
17. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
18. Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 Suppl):58-61.
19. Lee TC, Glynn RJ, Pena JM, Paynter NP, Conen D, Ridker PM, et al. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study. PloS One. 2011;6(12):e27670.
20. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30(3):561-7.
21. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104(1):9-14.
22. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194-202.
23. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2(5):307-14.
24. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674-85.
25. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer. 2012;19(5):F27-45.
26. Kabat GC, Kim MY, Peters U, Stefanick M, Hou L, Wactawski-Wende J, et al. A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. Eur J Cancer Prev. 2012;21(4):326-32.
27. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314(1):1-16.
28. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-808.
29. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2569-78.
30. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12(7):465-77.
31. Christensen AI, Davidsen M, Ekholm O, Hansen SE, Holst M, Juel K. The Nationale Health Profile 2010 ("den nationale sundhedsprofil 2010 - hvordan har du det?"). Copenhagen, Denmark: The National Board of Health (Sundhedsstyrelsen); 2011.
32. Christensen AI, Ekholm O, Glumer C, Andreasen AH, Hvidberg MF, Kristensen PL, et al. The Danish National Health Survey 2010. Study design and respondent characteristics. Scand J Public Health. 2012;40(4):391-7.
33. Ridderstrale M, Gudbjornsdottir S, Eliasson B, Nilsson PM, Cederholm J, Steering Committee of the Swedish National Diabetes R. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med. 2006;259(3):314-22.
34. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38:264-70. Diabetes care 2015, 38(4):734-735.
35. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. Ann Oncol. 2014;25(10):2065-72.
36. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948-58.
37. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 2008;17(11):1039-49.
38. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sorensen R, Lindhardsen J, et al. Risk of cancer in patients using glucoselowering agents: a nationwide cohort study of 3.6 million people. BMJ Open. 2012;2:e000433.
39. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J Cancer Res Ther. 2012;8(2):176-83.
40. Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol. 2013;45(3):745752.
41. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2122-32.
42. Wu X, Groves FD, McLaughlin CC, Jemal A, Martin J, Chen VW. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control. 2005;16(3):309-20.
43. Mellbin LG, Anselmino M, Ryden L. Diabetes, prediabetes and cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010;17 Suppl 1:S9-14.
44. Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015;172(5):627-38.
45. Kronborg CN, Hallas J, Jacobsen IA. Prevalence, awareness, and control of arterial hypertension in Denmark. J Am Soc Hypertens. 2009;3(1):19-24. e12.
46. Wuerzner G, Burnier M, Waeber B. Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vasc Health Risk Manag. 2011;7:741-7.
47. Collaboration ARBT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623-35.
48. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107(7):1028-33.
49. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-36.
50. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-convertingenzyme inhibitors or angiotensin-receptor blockers and cancer risk: a metaanalysis of observational studies. CMAJ. 2011;183(14):E1073-1084.
51. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen TJ, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol. 2013;167(5):2162-6.